# PREMARKET NOTIFICATION 510(K) SAFETY AND EFFECTIVENESS SUMMARY (as required by 21 CFR $\ S$ 807.92)

A. 510(k)Number: K112996   
B. Purpose for Submission: New device   
C. Measurand: Anti-nuclear antibodies   
D. Type of Test: Qualitative enzyme immunoassay   
E. Applicant: EUROIMMUN US INC.   
F. Proprietary and Established Names: EUROIMMUN Anti-ENA Pool ELISA (IgG)

G. Regulatory Information:

1. Requlation: 21 CFR 866.5100 - Antinuclear antibody immunological test system   
2. Classification: Class II   
3. Product code: LJM   
4. Panel: Immunology

H. Intended Use: 1. Intended use(s): The EUROlMMUN Anti-ENA Pool ELISA (IgG) is intended for the qualitative determination of IgG class antibodies against nuclear antigens (mixture of nRNP/Sm, Sm, SS-A (SS-A 60/Ro-52), SS-B, Scl-70 and rbmal P proteins) in human serum. It is used as an aid i the dignosis of mied conective tue diseases (MCTD), systemic lupus erythematosus, Sjögren's syndrome and progressive systemic sn conjucin wit ther aboatoy an cncal ndis. 2. Indication(s) for use: Same as intended use. 3. Special conditions for the use statement(s): For prescription use only. 4. Special instrument requirements: Microwell plate reader capable of measuring OD at 450nm and at 620nm for dual wavelenath readinas.

I. Device Description:

The EUROIMMUN Anti-ENA Pool Screen ELISA (IgG) consists of a microwell ELISA plate coated with a mixture of nRNP/Sm, Sm, SS-A (SS-A 60/Ro-52), SS-B, Sci-70 and ribosomal P proteins and antigens, clirator positivend negative control peroidase-abelle anti-human Gconjugate samplebufr wash buffer concentrate, TMB chromogen/substrate solution and stop solution.

# J. Substantial Equivalence Information:

1. Predicate device name (s): Aesku Aeskulisa ANA Hep-2   
2. Predicate 510(k) number(s): K081104   
3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Detection of IgG antibodies to nuclear antigens</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay format</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay platform</td><td rowspan=1 colspan=1>96-well microtiter plates</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Relative evaluation</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>Anti-human IgG labeled with horseradish peroxidase</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=1>TMB</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample types</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Procedure</td><td rowspan=1 colspan=1>Sample incubation with micro-well antigen coated plate,followed by a wash step, incubation with an anti-humanIgG enzyme conjugate; wash step, incubation withsubstrate; then the addition of a stop solution andreading at 450nm.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reported results</td><td rowspan=1 colspan=1>OD Ratio</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Cut off level</td><td rowspan=1 colspan=1>Ratio 1.0</td><td rowspan=1 colspan=1>Same</td></tr></table>

Differences   

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device.</td></tr><tr><td rowspan=1 colspan=1>Antigen mixture</td><td rowspan=1 colspan=1>nRNP/Sm, Sm, SS-A (SS-A 60/Ro-52), SS-B, Scl-70and ribosomal P proteins</td><td rowspan=1 colspan=1>dsDNA, histones, SS-A (Ro), SS-B (La), Sm,snRNP/Sm, Scl-70, Jo-1 and centromeric antigens andlysed HEp-2 cells</td></tr><tr><td rowspan=1 colspan=1>Calibrators andcontrols</td><td rowspan=1 colspan=1>1 calibrator2 controls: 1 positive, 1 negative</td><td rowspan=1 colspan=1>3 controls: 1 positive, 1 cut-off (used for calculation ofresults), 1 negative</td></tr><tr><td rowspan=1 colspan=1>Sample buffer</td><td rowspan=1 colspan=1>Ready for use</td><td rowspan=1 colspan=1>5x concentrate</td></tr><tr><td rowspan=1 colspan=1>Wash buffer</td><td rowspan=1 colspan=1>10x concentrate</td><td rowspan=1 colspan=1>50x concentrate</td></tr><tr><td rowspan=1 colspan=1>Stop solution</td><td rowspan=1 colspan=1>0.5 M sulphuric acid</td><td rowspan=1 colspan=1>1 M hydrochloric acid</td></tr><tr><td rowspan=1 colspan=1>Sample dilution</td><td rowspan=1 colspan=1>1:201</td><td rowspan=1 colspan=1>1:101</td></tr></table>

# <.Standard/Guidance Document Referenced (if applicable):

Guidance for Industry and FDA Staff Recommendations for Anti-Nuclear Antibody (ANA) Test System Premarket (510(k)) Submissions (January 22, 2009)

# L. Test Principle:

Patient samples are diluted 1:201in sample buffer, 100 µlof each diluted patient sample and pre-iluted conols and calirator ae aded to the antigenmixture coatedmicotiter wells and incubatedor 30iues at room temperature. After incubation the microtiter well strips are washed with wash buffer to remove unbound antibodies and 100 µlof the anti-human IgG enzyme conjugate reagent is added to each micotiter well. After an additional 30-minutes incubation at room temperature, the microtiter wells are again washed 3 ties with 300  of wash buffer to remove any unbound enzyme conjugate and 0 ul  te chrooen sustrate is added.The strips are incubated or15 minutes at room temperature and 00 u stop soluin s added. The microtiter plates are placed in an ELISA reader and read at a wavelength o $4 5 0 n m$ and a reference wavelength of between 620 nm and 650 nm within 30 minutes.

# M.Performance Characteristics (where applicable):

1Analytical performance:

a.Precision/Reproducibility:

The reproducibility of the test was investigated using sera with different concentrations. Intra-assay repducibility isbased n determinations n inter-assay producibility determination peoed ndiffent ns   das wit uns per ay ech  peoed with  epls according to the package insert. The following results were obtained:

Intra-Assay Reproducibility   

<table><tr><td rowspan=2 colspan=1>n = 20</td><td rowspan=1 colspan=8>Anti-ENA Pool ELISA (IgG) Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td><td rowspan=1 colspan=2>Sample 7   Sample 8</td></tr><tr><td rowspan=1 colspan=1>Mean Value (x):</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>7.4</td></tr><tr><td rowspan=1 colspan=1>Range of Values:</td><td rowspan=1 colspan=1>0.3-0.4</td><td rowspan=1 colspan=1>0.7-0.8</td><td rowspan=1 colspan=1>1.3-1.4</td><td rowspan=1 colspan=1>2.2-2.6</td><td rowspan=1 colspan=1>5.4-6.0</td><td rowspan=1 colspan=1>7.8-9.0</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>6.8-7.6</td></tr><tr><td rowspan=1 colspan=1>Expected Result:</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>%_ negative:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=2 colspan=1></td><td rowspan=2 colspan=1>Sample 9</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Sample 10</td><td rowspan=1 colspan=1>Sample 11</td><td rowspan=1 colspan=1>Sample 12</td><td rowspan=1 colspan=1>Sample 13</td><td rowspan=1 colspan=1>Sample 14</td><td rowspan=1 colspan=1>Sample 15</td><td rowspan=1 colspan=1>Sample 16</td></tr><tr><td rowspan=1 colspan=1>Mean Value (x):</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>2.8</td></tr><tr><td rowspan=1 colspan=1>Range of Values:</td><td rowspan=1 colspan=1>2.5-3.0</td><td rowspan=1 colspan=1>4.7 - 5.2</td><td rowspan=1 colspan=1>2.1-2.7</td><td rowspan=1 colspan=1>8.0-8.6</td><td rowspan=1 colspan=1>9.5 - 11.1</td><td rowspan=1 colspan=1>2.0-2.3</td><td rowspan=1 colspan=1>4.9-6.2</td><td rowspan=1 colspan=1>2.5-3.0</td></tr><tr><td rowspan=1 colspan=1>Expected Result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr></table>

Table 5.1.1.2 Inter-assay reproducibility   

<table><tr><td rowspan=2 colspan=1>n = 30</td><td rowspan=1 colspan=7>Anti-ENA Pool ELISA (IgG) Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=3>Sample 5   Sample 6   Sample 7</td></tr><tr><td rowspan=1 colspan=1>Mean Value (x)</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>8.4</td><td rowspan=1 colspan=1>0.2</td></tr><tr><td rowspan=1 colspan=1>Range of Values:</td><td rowspan=1 colspan=1>0.3-0.5</td><td rowspan=1 colspan=1>0.7-0.9</td><td rowspan=1 colspan=1>1.2-1.4</td><td rowspan=1 colspan=1>2.5-3.0</td><td rowspan=1 colspan=1>4.9-6.1</td><td rowspan=1 colspan=1>7.6-9.1</td><td rowspan=1 colspan=1>0.2-0.3</td></tr><tr><td rowspan=1 colspan=1>Expected Result:</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=2 colspan=1></td><td rowspan=2 colspan=1>Sample 8</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Sample 9</td><td rowspan=1 colspan=1>Sample 10</td><td rowspan=1 colspan=1>Sample 11</td><td rowspan=1 colspan=1>Sample 12</td><td rowspan=1 colspan=1>Sample 13</td><td rowspan=1 colspan=1>Sample 14</td></tr><tr><td rowspan=1 colspan=1>Mean Value (x):</td><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>7.1</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>Range of Values:</td><td rowspan=1 colspan=1>5.3-7.3</td><td rowspan=1 colspan=1>1.5-2.8</td><td rowspan=1 colspan=1>2.6-4.9</td><td rowspan=1 colspan=1>1.1-2.1</td><td rowspan=1 colspan=1>5.4-8.9</td><td rowspan=1 colspan=1>4.5-9.8</td><td rowspan=1 colspan=1>1.6-2.4</td></tr><tr><td rowspan=1 colspan=1>Expected Result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr></table>

T L with C samples distributed over the measurement range. The following results were obtained:

Lot to Lot Reproducibility b. Linearity/assay reportable range: Not applicable.

Anti-ENA Pool ELISA (IgG)   

<table><tr><td rowspan=1 colspan=1>Sample 1Ratio</td><td rowspan=1 colspan=1>Sample 2Ratio</td><td rowspan=1 colspan=1>Sample 3Ratio</td><td rowspan=1 colspan=1>Sample 4Ratio</td><td rowspan=1 colspan=1>Sample 5Ratio</td><td rowspan=1 colspan=1>Sample 6Ratio</td><td rowspan=1 colspan=1>Sample 7Ratio</td><td rowspan=1 colspan=1>Sample 8Ratio</td></tr><tr><td rowspan=1 colspan=1>n:</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>11**</td><td rowspan=1 colspan=1>Wl</td><td rowspan=1 colspan=1>9**</td><td rowspan=1 colspan=1>11**</td><td rowspan=1 colspan=1>11**</td><td rowspan=1 colspan=1>9**</td></tr><tr><td rowspan=1 colspan=1>Mean Value (x):</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>W</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>8.5</td></tr><tr><td rowspan=1 colspan=1>Range of Values:</td><td rowspan=1 colspan=1>1.1- 1.2</td><td rowspan=1 colspan=1>0.8-0.9</td><td rowspan=1 colspan=1>0.1- 0.2</td><td rowspan=1 colspan=1>W</td><td rowspan=1 colspan=1>2.5-3.3</td><td rowspan=1 colspan=1>3.0-4.2</td><td rowspan=1 colspan=1>4.1-5.7</td><td rowspan=1 colspan=1>7.0-9.8</td></tr><tr><td rowspan=1 colspan=1>Expected Result:</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>W</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>Wll</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr></table>

/.Omitte, Replaced by Sample 1s

Anti-ENA Pool ELISA (IgG)   

<table><tr><td rowspan=2 colspan=5>Sample 9  Sample 10 Sample 11 Sample 12Ratio        Ratio        Ratio        Ratio</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Sample 9Ratio</td><td rowspan=1 colspan=1>Sample 10Ratio</td><td rowspan=1 colspan=1>Sample 11Ratio</td><td rowspan=1 colspan=1>Sample 12Ratio</td><td rowspan=1 colspan=1>Sample 13Ratio</td><td rowspan=1 colspan=1>Sample 14Ratio</td><td rowspan=1 colspan=1>Sample 15Ratio</td><td rowspan=1 colspan=1>Sample 16Ratio</td></tr><tr><td rowspan=1 colspan=1>n:</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td><td rowspan=1 colspan=1>6*</td></tr><tr><td rowspan=1 colspan=1>Mean Value (x):</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>Range of Values:</td><td rowspan=1 colspan=1>0.1 - 0.3</td><td rowspan=1 colspan=1>5.5- 7.6</td><td rowspan=1 colspan=1>1.9-3.0</td><td rowspan=1 colspan=1>2.9 - 5.2</td><td rowspan=1 colspan=1>1.9-2.7</td><td rowspan=1 colspan=1>5.9-8.2</td><td rowspan=1 colspan=1>7.0-9.7</td><td rowspan=1 colspan=1>1.8-2.3</td></tr><tr><td rowspan=1 colspan=1>Expected Result:</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr></table>

\*3 lots x 2 runs \*\* n lots x 1 run   
Additional Samples Run

<table><tr><td rowspan=1 colspan=1>No.</td><td rowspan=1 colspan=1>Lot</td><td rowspan=1 colspan=1>Test</td><td rowspan=1 colspan=1>Sample 9Ratio</td><td rowspan=1 colspan=1>Sample 10Ratio</td><td rowspan=1 colspan=1>Sample 11Ratio</td><td rowspan=1 colspan=1>Sample 12Ratio</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>5.2</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>5.0</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>3.4</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>3.4</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>3.2</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>2.9</td></tr><tr><td rowspan=1 colspan=1>No.</td><td rowspan=1 colspan=1>Lot</td><td rowspan=1 colspan=1>Test</td><td rowspan=1 colspan=1>Sample 13Ratio</td><td rowspan=1 colspan=1>Sample 14Ratio</td><td rowspan=1 colspan=1>Sample 15Ratio</td><td rowspan=1 colspan=1>Sample 16Ratio</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>8.1</td><td rowspan=1 colspan=1>9.7</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>9.7</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3 $</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>6.2</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>1.8</td></tr></table>

C. High dose Hook effect

Potential for a high dose Hook effect is a phenomenon that is inherent with one step "sandwich" assay designs: Very high concentrations of antigen in the patient sample bind to all available sites - saturating them - on both the antibody-solid phase and the antibody-labeled conjugate and thereby prevent  sandwich foratin. Under thes conditions, hemeasured levl  analyty sificanty lower than he actual lvel present in the sampleThe two-stemoassay desi the Anti-ENA Pool ELISA (IgG) eliminates the adverse contribution of binding proteins, endogenous interfering substances and general matrix effects due to the extra wash step.

d. Traceability, Stability, Expected values (controls, calibrators or methods): A recognized standard or reference material for anti-nuclear antibodies is not available. Results of this assay are given in ratios. The reactivity of the Anti-ENA Pool ELISA (IgG) was verified using the CDC ANA reference panel.

e. Limit of detection: Not applicable.

Analytical specificity.

Cross-reactivity: The quality of the antigen mixture coated on the plates, containing the antigens nRNP/Sm, Sm, SS-A (SS-A 60/Ro-52), SS-B, Scl-70 and ribosomal P-proteins, ensures a high specificity of the ELISA. The reactivity of the assay was confirmed using the CDC ANA reference panel. CDC sample No. 10, characterized as anti-Jo-1 positive, was found positive due to Ro-52 antibodies which commonly occur in anti-Jo-1 positive samples. As the definition of CDC sample No. 10 did not include a check for Ro-52 antibodies, anti-Jo-1 positive samples that were negative for anti-Ro-52 were tested and found negative, while samples positive for both anti-Jo-1 and anti-Ro-52 were found positive, so no cross-reactivity to Jo-1 is expected. Cross reactivity was investigated using a total of 82 clinically and serologically characterized samples (10 celiac disease for antibodies against gliadin and tissue transglutaminase, 17 Wegener's granulomatosis for ANCA, 39 rheumatoid arthritis for antibodies against CCP and 16 infectious diseases antibody positive samples). All except of 2 samples were negative in the Anti-ENA Pool ELISA (IgG), so no cross reactivity is expected.

Interference: To investigate the influence from hemoglobin, triglycerides and bilirubin, 4 different specimens at different ANA concenitrations (ratio $0 . 7 - 8 . 4 )$ were spiked with potential interfering substances and were incubated with the test system. The recovery in relation to the unspiked sample without interferent was calculated. The individual recovery of the positive or borderline samples was within the range of $9 1 - 1 0 5 \%$ . No significant interference was observed for concentrations of up to 1000 mg/dl for hemoglobin, $2 0 0 0 \ m g / { \mathsf { d } } |$ for triglyceride and 40 mg/dl for bilirubin. Furthermore, the influence from heumatoid factor was investigated by spiking f 6 diffeent speciments wih a heumatoid factor positive material characterized nephelometricaly). The recoveryn relation to the original sample (not spiked) was calculated. The recoveries were found within $9 6 - 1 0 6 \%$ . No interference was observed with rheumatoid factor at $5 0 0 ~ | \downarrow | / m |$ .

g. Assay cut-off: Ratio 1.0

2Comparison studies:

a. Method comparison with predicate device:

A comparison study was performed using 278 clinically characterized samples from patients and control groups (49 mixed connective tissue diseases, 26 systemic lupus erythematosus, 29 Sjögren's syndrome, 22 systemic sclerosis, 20 polymyositis/dermatomyositis, 10 celiac disease, 17 Wegener's granulomatosis, 39 rheumatoid arthritis, 6 infectious disease and 50 healthy), obtained from different sources. The panel consisted of 100 men and 164 women with 14 unknown. Age ranged from 7 to 87 years with an average age of 46 years (15 unknown). The samples were tested with the EUROIMMUN Anti-ENA Pool ELISA (IgG) and with the Aesku Aeskulisa ANA Hep-2 as the predicate device. The results are. shown in the table below. All discrepant samples were from controls.

<table><tr><td colspan="4">n = 278</td><td colspan="4">Predicate ELISA</td></tr><tr><td colspan="4">EUROIMMUN</td><td colspan="3">positive</td></tr><tr><td rowspan="2">Anti-ENA Pool ELISA (IgG)</td><td colspan="3">positive</td><td colspan="2">135</td><td colspan="2">negative 1</td></tr><tr><td>negative</td><td></td><td></td><td>3.</td><td></td><td>139</td></tr><tr><td>Negative agreement</td><td>139 1</td><td>140</td><td>=</td><td>99.3%</td><td>95% C.I.: 96.1%</td><td>- 100.0%</td></tr><tr><td>Positive agreement</td><td>135 1</td><td>138</td><td>= 97.8%</td><td>95% C.I.:</td><td>93.8% -</td><td>99.5%</td></tr><tr><td>Overall agreement</td><td>274 1</td><td>278</td><td>= 98.6%</td><td>95% C.I.:</td><td>96.4% •</td><td>99.6%</td></tr></table>

b. Matrix comparison: Not applicable.

Clinical studies:

Cliical tudes wee perormedincoperation wihdifferent  In oal clinicallyharactiz samples were investigated for ENA antibodies (IgG). The EUROIMMUN Anti-ENA Pool ELISA (IgG) showed an overall sensitivity of $60 . 9 \%$ $9 5 \%$ C.: $5 4 . 7 - 6 6 . 9 \% )$ and a specificity of $9 6 . 5 \%$ $( 9 5 \%$ C.I.: 92.5 $- 9 8 . 7 \% )$ The results are shown in the table below. $9 5 \%$ C.I. are calculated by the exact method.

aClinical sensitivity.

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>Anti-ENA Pool ELISA (IgG)</td></tr><tr><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Mixed connective tissue disease</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>92.0- 100.0%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Systemic lupus erythematosus</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>55.3%</td><td rowspan=1 colspan=1>44.1-66.1%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Systemic sclerosis</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>45.5%</td><td rowspan=1 colspan=1>33.1 - 58.2%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>Sjogren&#x27;s syndrome</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>72.7%</td><td rowspan=1 colspan=1>60.4-83.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>261</td><td rowspan=1 colspan=1>159</td><td rowspan=1 colspan=1>60.9%</td><td rowspan=1 colspan=1>54.7- 66.9%</td></tr></table>

Clinical specificity.

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>Anti-ENA Pool ELISA (IgG)</td></tr><tr><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Polymyositis/dermatomyositis</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>84.6%</td><td rowspan=1 colspan=1>65.1-95.6%</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>Celiac disease</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>83.9 - 100.0%</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>Wegener&#x27;s granulomatosis</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>88.2%</td><td rowspan=1 colspan=1>63.6 - 98.5%</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>Rheumatoid arthritis</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>91.0 - 100.0%</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>Other autoimmune diseases*</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>93.2- 100.0%</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>Bacterial/viral infections</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>79.4-100.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>171</td><td rowspan=1 colspan=1>165</td><td rowspan=1 colspan=1>96.5%</td><td rowspan=1 colspan=1>92.5  98.7%</td></tr></table>

u

C. Other clinical supportive data (when a. and $b$ are not applicable): Not applicable.

4. Clinical cut-off: See Assay cut-off.

1

5. Expected values/Reference range:

The levels of ANA (IgG) were analyzed in a panel of 200 samples from apparently healthy blood donors (mixed age and sex). The results are shown in the table below.

<table><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Positives</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Negatives</td><td rowspan=1 colspan=1>197</td></tr><tr><td rowspan=1 colspan=1>Prevalence</td><td rowspan=1 colspan=1>1.5%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Ratio</td></tr><tr><td rowspan=1 colspan=1>Lowest value</td><td rowspan=1 colspan=1>0.0</td></tr><tr><td rowspan=1 colspan=1>Highest value</td><td rowspan=1 colspan=1>5.0</td></tr><tr><td rowspan=1 colspan=1>Mean value</td><td rowspan=1 colspan=1>0.2</td></tr><tr><td rowspan=1 colspan=1>Std deviation</td><td rowspan=1 colspan=1>0.37</td></tr></table>

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809. 10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

Signature   
Michael Locke, Dir. Of Regulatory Affairs   
Typed Name, Title

Euroimmun US Inc. c/o Ms. Kathryn Kohl Managing Director 1 100 The American Road Morris Plains, NJ 07950

Re: k112996 Trade/Device Name: EUROIMMUN Anti-ENA Pool ELISA (IgG) Regulation Number: 21 CFR $\ S 8 6 6 . 5 1 0 0 $ EY Regulation Name: Antinuclear Antibody Immunological Test System Regulatory Class: Class II Product Code: LLL Dated: March 28, 2013 Received: April 3, 2013

Dear Ms. Kohl:

We have reviewed your Section $5 1 0 ( \mathbf { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or classIII (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Regster.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http:/www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucmI 15809.htmn for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

# Maria M Chan -S

Maria M. Chan, Ph.D.   
Director   
Division of Immunology and Hematology Devices Office of In Vitro Diagnostics and Radiological Health   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): k112996

Device Name: EUROIMMUN Anti-ENA Pool ELISA (IgG)

Indications For Use:

The EUROIMMUN Anti-ENA Pool ELISA (igG) is intended for the qualitative determination of IgG class antibodies against nuclear antigens (mixture of nRNA/Sm, Sm, SS-A (SS-A 60/Ro-52), SS-B, Scl-70, and ribosomal $\mathsf { P }$ proteins) in human serum. It is used as an aid in the diagnosis of mixed connective tissue disease (MCTD), systemic lupus erythematosus, Sjögren's syndrome and progressive systemic sclerosis, in conjunction with other laboratory and clinical findings.